Actively Recruiting
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
Led by University of Aarhus · Updated on 2024-12-05
200
Participants Needed
1
Research Sites
211 weeks
Total Duration
On this page
Sponsors
U
University of Aarhus
Lead Sponsor
A
Aarhus University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.
CONDITIONS
Official Title
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with colorectal liver metastases planned for resection
- At least one tumor size >=3cm
- Performance status 0-1
You will not qualify if you...
- Liver cirrhosis
- Extrahepatic metastases that can not be addressed curatively
- Other malignant diseases within 5 years prior to diagnosis
- Prior RFA treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Aarhus University Hospital, Department of Surgery
Aarhus, Denmark, 8200
Actively Recruiting
Research Team
J
Jakob Kirkegård, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here